Skip to content

Effect of the glucagon-like peptide-1 receptor agonist on atherosclerosis in patient with impaired glucose tolerance

Effect of Liraglutide on Atherosclerosis in Patients with Impaired Glucose Tolerance

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063693
Enrollment
Unknown
Registered
2022-09-14
Start date
2022-09-10
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

impaired glucose tolerance

Interventions

Lifestyle intervention group:Intervention to improve life style, including balanced diet (i.e. each person should eat 200g-300g protein, 500g fresh vegetables, 250g Cereals, < 20g vegetable oil, < 6G
Regular exercise (i.e. walking for 3 km every day for more than 30 min, at least 5 times a&#
Liraglutide group:On the basis of lifestyle improvement intervention, subcutaneous injection of liraglutide / Novolin was given

Sponsors

Qingdao Chengyang District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The inclusion criteria were adults aged 20–75 years, overweight or obese (BMI 27–40 kg/m2), and diagnosed with IGT. Glucose tolerance status was defined on the basis of oral glucose tolerance test (OGTT) using the World Health Organization criteria

Exclusion criteria

Exclusion criteria: 1) diagnosed with type 1 or 2 diabetes, 2) had lower limb ischemia, 3) treated with hypoglycemic drugs or angiotensin converting enzyme inhibitor/angiotensin II receptor antagonist during the trial, 4) had chronic diseases or health conditions, 5) had acute illness (i.e. infection), or 6) pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
blood glucose;insulin;glycosylated hemoglobin;blood pressure;lood lipids;white blood cell;tumor necrosis factor a;Hypersensitive C-reactive protein;Interleukin-6;Interleukin-1 ß;Interleukin-2 a;Carotid intima-media thickness;

Countries

china

Contacts

Public ContactRao xiao-pang
123raoxiaopang@163.com17806231065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026